Andrade, S. E., Kahler, K. H., Frech, F., &; Chan, K. A. (2006). Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf, 15(8), 565-574; discussion 575-567. doi: 10.1002/pds.1230
Bangalore, S., Kamalakkannan, G., Parkar, S., &; Messerli, F. H. (2007). Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 120(8), 713-719. doi: 10.1016/j.amjmed.2006.08.033
Bashir, S., Sherwani, M. U., Shabbir, I., &; Batool, A. (2011). Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. J Ayub Med Coll Abbottabad, 23(3), 97-100.
Bourgault, C., Senecal, M., Brisson, M., Marentette, M. A., &; Gregoire, J. P. (2005). Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens, 19(8), 607-613. doi: 10.1038/sj.jhh.1001873
Bushnell, C. D., Olson, D. M., Zhao, X., Pan, W., Zimmer, L. O., Goldstein, L. B., . . . Investigators, A. (2011). Secondary preventive medication persistence and adherence 1 year after stroke. Neurology, 77(12), 1182-1190. doi: 10.1212/WNL.0b013e31822f0423
Castilla-Guerra, L., &; Fernandez-Moreno Mdel, C. (2012). Update on the management of hypertension for secondary stroke prevention. Eur Neurol, 68(1), 1-7. doi: 10.1159/000336836
Fagan, S. C., &; Hess, D. C. (2014). Chapter 10. Stroke. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells &; L. M. Posey (Eds.), Pharmacotherapy: A Pathophysiologic Approach, 9e. New York, NY: The McGraw-Hill Companies.
Furie, K. L., Kasner, S. E., Adams, R. J., Albers, G. W., Bush, R. L., Fagan, S. C., . . . Outcomes, R. (2011). Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke, 42(1), 227-276. doi: 10.1161/STR.0b013e3181f7d043
Glader, E. L., Sjolander, M., Eriksson, M., &; Lundberg, M. (2010). Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke, 41(2), 397-401. doi: 10.1161/STROKEAHA.109.566950
Gorelick, P. B. (1995). Stroke prevention. Arch Neurol, 52(4), 347-355.
Gradman, A. H., Basile, J. N., Carter, B. L., &; Bakris, G. L. (2010). Combination therapy in hypertension. J Am Soc Hypertens, 4(1), 42-50. doi: 10.1016/j.jash.2010.02.005
Group, P. C. (1995). Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl), 108(9), 710-717.
Group, P. C. (2001). Randomised trial of a Perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358(9287), 1033-1041. doi: 10.1016/S0140-6736(01)06178-5
Howard, V. J., McClure, L. A., Meschia, J. F., Pulley, L., Orr, S. C., &; Friday, G. H. (2006). High prevalence of stroke symptoms among persons without a diagnosis of stroke or transient ischemic attack in a general population: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Arch Intern Med, 166(18), 1952-1958. doi: 10.1001/archinte.166.18.1952
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., . . . Ortiz, E. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311(5), 507-520. doi: 10.1001/jama.2013.284427
Kamat, S. A., Bullano, M. F., Chang, C. L., Gandhi, S. K., &; Cziraky, M. J. (2011). Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin, 27(5), 961-968. doi: 10.1185/03007995.2011.562494
Kauf, T. L., Davis, K. L., Earnshaw, S. R., &; Davis, E. A. (2012). Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence, 6, 155-164. doi: 10.2147/PPA.S28482
Kumagai, H., Sakata, K., Matsuura, T., Imai, M., Onami, T., Iigaya, K., &; Saruta, T. (2002). [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis]. Nihon Rinsho, 60(10), 2005-2013.
Law, M. R., Morris, J. K., &; Wald, N. J. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, b1665. doi: 10.1136/bmj.b1665
Methodology, W. C. C. f. D. S. (2013). Guidelines for ATC classification and DDD assignment 2014. In W. C. Centre (Ed.). Oslo.
Mohan, K. M., Wolfe, C. D., Rudd, A. G., Heuschmann, P. U., Kolominsky-Rabas, P. L., &; Grieve, A. P. (2011). Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke, 42(5), 1489-1494. doi: 10.1161/STROKEAHA.110.602615
Moser, M., &; Feig, P. U. (2009). Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med, 169(20), 1851-1856. doi: 10.1001/archinternmed.2009.342
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., . . . investigators, I. (2010). Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 376(9735), 112-123. doi: 10.1016/S0140-6736(10)60834-3
Prabhakaran, S., &; Chong, J. Y. (2014). Risk factor management for stroke prevention. Continuum (Minneap Minn), 20(2 Cerebrovascular Disease), 296-308. doi: 10.1212/01.CON.0000446102.82420.64
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., . . . Stroke Statistics, S. (2012). Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation, 125(1), e2-e220. doi: 10.1161/CIR.0b013e31823ac046
Saseen, J. J., MacLaughlin, E. J., &; Westfall, J. M. (2003). Treatment of uncomplicated hypertension: are ACE inhibitors and calcium channel blockers as effective as diuretics and beta-blockers? J Am Board Fam Pract, 16(2), 156-164.
Schrader, J., Luders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., . . . Group, M. S. (2005). Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke, 36(6), 1218-1226. doi: 10.1161/01.STR.0000166048.35740.a9
Wing, L. M., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L., . . . West, M. J. (2003). A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med, 348(7), 583-592. doi: 10.1056/NEJMoa021716
中央健康保險署. (2012). 全民健康保險醫療統計年報. 衛生福利部.
台灣腦中風學會. (2008). 台灣腦中風防治指引2008.
吳冠穎, 吳肖琪, 洪燕妮,吳君誠,林麗嬋,胡漢華. (2012). 台灣腦中風病人急性後期照護需要之探討. 臺灣公共衛生雜誌, 31(3), 251-262.統計處. (2012). 民國101年主要死因分析. 衛生福利部.
廖建彰, 李采娟, 林瑞雄, 與宋鴻樟. (2006). 2000年台灣腦中風發生率與盛行率的城鄉差異. [Urban and Rural Difference in Prevalence and Incidence of Stroke in 2000 in Taiwan]. 臺灣公共衛生雜誌, 25(3), 223-230.衛生福利部食品藥物管理署. (2014). 西藥、醫療器材、含藥化粧品許可證查詢. Retrieved Jul 12, 2014, from http://www.fda.gov.tw/MLMS/(S(y5ncsi55vn1sbjmu41bvjke2))/H0001.aspx